23,064 results match your criteria Br. J. Cancer[Journal]


A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours.

Br J Cancer 2019 Apr 17. Epub 2019 Apr 17.

Sarah Cannon Research Institute, London, UK.

Background: Combined focal adhesion kinase (FAK) and MEK inhibition may provide greater anticancer effect than FAK monotherapy.

Methods: This dose-finding phase Ib study (adaptive 3 + 3 design) determined the maximum tolerated dose (MTD) of trametinib and the FAK inhibitor GSK2256098 in combination. Eligible patients had mesothelioma or other solid tumours with probable mitogen activated protein kinase pathway activation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0452-3DOI Listing

Reduction of cervical cancer incidence within a primary HPV screening pilot project (WOLPHSCREEN) in Wolfsburg, Germany.

Br J Cancer 2019 Apr 16. Epub 2019 Apr 16.

Department of Obstetrics and Gynecology, Klinikum Wolfsburg, Wolfsburg, Germany.

Background: Randomised controlled trials showed human papillomavirus (HPV)-based screening leads to a significant reduction in cervical cancer incidence compared with cytology-based screening only.

Methods: Non-hysterectomised participants ≥30 years underwent co-testing with Papanicolaou (Pap) smear and HR-HPV testing (Hybrid Capture 2; HC2). Women with normal findings had their next screening round after 5 years, and HC2+ and Pap abnormal cases were immediately referred for colposcopy, while cases with discordant findings had repeat testing after 12 months with referral to colposcopy in cases with persistent positive findings. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41416-019-0453-2
Publisher Site
http://dx.doi.org/10.1038/s41416-019-0453-2DOI Listing
April 2019
1 Read

Low tumour PPM1H indicates poor prognosis in colorectal cancer via activation of cancer-associated fibroblasts.

Br J Cancer 2019 Apr 16. Epub 2019 Apr 16.

Department of Colorectal Surgery, Changhai Hospital, Second Military Medical University, 168 Changhai Rd., Shanghai, 200433, China.

Background: Vimentin (VIM) is considered a prognostic marker in colorectal cancer (CRC). Our aim is to identify genes that fulfil a "X-low implies VIM-high" Boolean relationship and to evaluate their prognostic value and potential mechanism.

Methods: Potential biomarkers related to VIM expression were searched using a bioinformatics approach across gene-expression arrays. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0450-5DOI Listing

Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08).

Br J Cancer 2019 Apr 16. Epub 2019 Apr 16.

University Hospitals of Vaud, Lausanne, Switzerland.

Background: Neoadjuvant chemotherapy (CT) followed by radiotherapy (RT) and surgery showed a median survival of 28.7 months in resectable stage IIIB non-small-cell lung cancer (NSCLC) patients (pts). Here, we evaluate the impact of concomitant cetuximab to the same neoadjuvant chemo-radiotherapy (CRT) in selected patients (pts) with NSCLC, stage IIIB. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0447-0DOI Listing

ECT2 associated to PRICKLE1 are poor-prognosis markers in triple-negative breast cancer.

Br J Cancer 2019 Apr 11. Epub 2019 Apr 11.

Centre de Recherche en Cancérologie de Marseille, Equipe labellisée 'Predictive oncology' Ligue 2018, Aix Marseille Université, Inserm, CNRS, Institut Paoli Calmettes, 13009, Marseille, France.

Background: Triple-negative breast cancers (TNBC) are poor-prognosis tumours candidate to chemotherapy as only systemic treatment. We previously found that PRICKLE1, a prometastatic protein involved in planar cell polarity, is upregulated in TNBC. We investigated the protein complex associated with PRICKLE1 in TNBC to identify proteins possibly involved in metastatic dissemination, which might provide new prognostic and/or therapeutic targets. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0448-zDOI Listing
April 2019
1 Read

International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation.

Br J Cancer 2019 Apr 11. Epub 2019 Apr 11.

Women's College Research Institute, Toronto, ON, Canada.

Background: Women with a BRCA1 or BRCA2 mutation face high risks of breast and ovarian cancer. In the current study, we report on uptake of cancer screening and risk-reduction options in a cohort of BRCA mutation carriers from ten countries over two time periods (1995 to 2008 and 2009 to 2017).

Methods: Eligible subjects were identified from an international database of female BRCA mutation carriers and included women from 59 centres from ten countries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0446-1DOI Listing

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.

Br J Cancer 2019 Apr 10. Epub 2019 Apr 10.

Quality of Life Office, International Breast Cancer Study Group Coordinating Center and Bern University Hospital, Inselspital, Bern, Switzerland.

Background: In the phase III SOLE trial, the extended use of intermittent versus continuous letrozole for 5 years did not improve disease-free survival in postmenopausal women with hormone receptor-positive breast cancer. Intermittent therapy with 3-month breaks may be beneficial for patients' quality of life (QoL).

Methods: In the SOLE QoL sub-study, 956 patients completed the Breast Cancer Prevention Trial (BCPT) symptom and further QoL scales up to 24 months after randomisation. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41416-019-0435-4
Publisher Site
http://dx.doi.org/10.1038/s41416-019-0435-4DOI Listing
April 2019
3 Reads

Family history of cancer and risk of paediatric and young adult's testicular cancer: A Norwegian cohort study.

Br J Cancer 2019 Apr 10. Epub 2019 Apr 10.

Institute of Health and Society, University of Oslo, P.O Box 1130 Blindervn, 0318, Oslo, Norway.

Background: The aim of this study was to examine the association of a family history of cancer with the risk of testicular cancer in young adults.

Methods: This is a prospective cohort study including 1,974,287 males born 1951-2015, of whom 2686 were diagnosed with TC before the age of 30.

Results: A history of TC in male relatives was significantly associated with a diagnosis of TC among children and young adults, including brothers (6. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0445-2DOI Listing
April 2019
3 Reads

Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma.

Br J Cancer 2019 Apr 10. Epub 2019 Apr 10.

Department of Oncology, Section of Radiotherapy, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

Intratumor heterogeneity may contribute to the ambiguous clinical results on PD-L1 status as a predictor for immunotherapy response in patients with HNSCC. This decreases the utility of PD-L1 expression from single tumour biopsies as a predictive biomarker. In this prospective study, intratumor heterogeneity of PD-L1 expression in HNSCC was investigated with both Tumour Proportion Score (TPS) and Combined Positive Score (CPS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0449-yDOI Listing

Increased expression of the immunosuppressive interleukin-35 in patients with non-small cell lung cancer.

Br J Cancer 2019 Apr 8. Epub 2019 Apr 8.

Department of Molecular Pneumology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.

Background: The immunosuppressive role of the cytokine IL-35 in patients with non-small cell lung cancer (NSCLC) is poorly understood. In this study, we analysed the localisation and regulation of IL-35 in the lung of patients with non-small cell lung cancer (NSCLC) to further elucidate the immune-escape of cancer cells in perioperative course of disease.

Methods: Interleukin 35 (IL-35) was measured by ELISA in postoperative serum from 7 patients with NSCLC as well as 8 samples from healthy controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0444-3DOI Listing

Sorafenib alone vs. sorafenib plus GEMOX as 1-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial.

Br J Cancer 2019 Apr 4. Epub 2019 Apr 4.

Gustave Roussy, Villejuif, France.

Background: Sorafenib remains one major first-line therapeutic options for advanced hepatocellular carcinoma (aHCC), with modest efficacy. We investigated the addition of gemcitabine and oxaliplatin (GEMOX) to sorafenib in aHCC patients.

Methods: Our multicentre phase II trial randomised aHCC first-line patients to sorafenib (400 mg BID) or sorafenib-GEMOX every 2 weeks (1000 mg/m gemcitabine; 100 mg/m oxaliplatin). Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41416-019-0443-4
Publisher Site
http://dx.doi.org/10.1038/s41416-019-0443-4DOI Listing
April 2019
5 Reads

Targeting β-catenin overcomes MEK inhibition resistance in colon cancer with KRAS and PIK3CA mutations.

Br J Cancer 2019 Apr 4. Epub 2019 Apr 4.

Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.

Background: Mitogen-activated protein kinases (MEK 1/2) are central components of the RAS signalling pathway and are attractive targets for cancer therapy. These agents continue to be investigated in KRAS mutant colon cancer but are met with significant resistance. Clinical investigations have demonstrated that these strategies are not well tolerated by patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0434-5DOI Listing

Harnessing the innate immune system and local immunological microenvironment to treat colorectal cancer.

Br J Cancer 2019 Apr 2. Epub 2019 Apr 2.

Department of Medical Oncology and Internal Medicine VI, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.

Significant progress in the development of new immunotherapies has led to successful clinical trials for malignant melanoma and non-small cell lung cancer; however, for the majority of solid tumours of the gastrointestinal tract, little or no progress has been seen. The efficacy of immunotherapies is limited by the complexities of a diverse set of immune cells, and interactions between the tumour cells and all other cells in the local microenvironment of solid tumours. A large fraction of immune cells present in and around solid tumours derive from the innate arm of the immune system and using these cells against tumours offers an alternative immunotherapeutic option, especially as current strategies largely harness the adaptive arm of the immune system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0441-6DOI Listing

The impact of immediate breast reconstruction on the time to delivery of adjuvant therapy: the iBRA-2 study.

Br J Cancer 2019 Mar 29. Epub 2019 Mar 29.

Linda McCartney Centre, Royal Liverpool and Broadgreen University Hospital, Prescot Street, Liverpool, L7 8XP, UK.

Background: Immediate breast reconstruction (IBR) is routinely offered to improve quality-of-life for women requiring mastectomy, but there are concerns that more complex surgery may delay adjuvant oncological treatments and compromise long-term outcomes. High-quality evidence is lacking. The iBRA-2 study aimed to investigate the impact of IBR on time to adjuvant therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0438-1DOI Listing

How rapid advances in imaging are defining the future of precision radiation oncology.

Br J Cancer 2019 Apr 26;120(8):779-790. Epub 2019 Mar 26.

Cancer Institute, University College London, London, UK.

Imaging has an essential role in the planning and delivery of radiotherapy. Recent advances in imaging have led to the development of advanced radiotherapy techniques-including image-guided radiotherapy, intensity-modulated radiotherapy, stereotactic body radiotherapy and proton beam therapy. The optimal use of imaging might enable higher doses of radiation to be delivered to the tumour, while sparing normal surrounding tissues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0412-yDOI Listing

Can proton therapy be considered a standard of care in oncology? Lessons from the United States.

Br J Cancer 2019 Apr 26;120(8):775-776. Epub 2019 Mar 26.

Massachusetts General Hospital, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-018-0324-2DOI Listing

Comment on "Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis".

Br J Cancer 2019 Mar 26. Epub 2019 Mar 26.

University of Adelaide, North Terrace Campus, Adelaide, SA, 5005, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0437-2DOI Listing

Reply to Comments on "Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis".

Br J Cancer 2019 Mar 26. Epub 2019 Mar 26.

MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, 90 High Holborn, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0440-7DOI Listing

Reply to Comment on "Improving clinical diagnosis of early-stage cutaneous melanoma based on Raman spectroscopy".

Br J Cancer 2019 Apr 22;120(8):865-866. Epub 2019 Mar 22.

Department of Dermatology, Erasmus MC, University Medical Center Rotterdam, room Ee-1691, P.O.Box 2040, 3000 CA, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0431-8DOI Listing
April 2019
2 Reads

Cell lines and immune classification of glioblastoma define patient's prognosis.

Br J Cancer 2019 Apr 22;120(8):806-814. Epub 2019 Mar 22.

Research Platform in Biological Oncology, Dijon, France.

Background: Prognostic markers for glioblastoma are lacking. Both intrinsic tumour characteristics and microenvironment could influence cancer prognostic. The aim of our study was to generate a pure glioblastoma cell lines and immune classification in order to decipher the respective role of glioblastoma cell and microenvironment on prognosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0404-yDOI Listing
April 2019
7 Reads

Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes.

Br J Cancer 2019 Mar 22. Epub 2019 Mar 22.

Anglo-Celtic Cooperative Oncology Group (ACCOG), Edinburgh, United Kingdom.

Background: We explored, within the EORTC10994 study, the outcomes for patients with molecular apocrine (MA) breast cancer, and defined immunohistochemistry (IHC) as androgen-receptor (AR) positive, oestrogen (ER) and progesterone (PR) negative. We also assessed the concordance between IHC and gene expression arrays (GEA) in the identification of MA cancers.

Methods: Centrally assessed biopsies for AR, ER, PR, HER2 and Ki67 by IHC were classified into six subtypes: MA, triple-negative (TN) basal-like, luminal A, luminal B HER2 negative, luminal B HER2 positive and "other". Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0420-yDOI Listing
March 2019
1 Read

Sexually transmitted infections and risk of epithelial ovarian cancer: results from the Nurses' Health Studies.

Br J Cancer 2019 Apr 21;120(8):855-860. Epub 2019 Mar 21.

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Background: Sexually transmitted infections (STIs) are associated with pelvic inflammatory disease and tubal pathologies. Given the tubal origin of a proportion of ovarian cancers, STIs may be relevant in their aetiology.

Methods: Antibodies indicating past infection with Chlamydia trachomatis, Mycoplasma genitalium, herpes simplex virus type 2, and against human papillomavirus oncogenes (L1 and E6+E7 oncoproteins of types 16, 18, 45) were measured in prediagnosis plasma samples in a nested case-control study in the Nurses' Health Studies (n = 337 cases 1:1 matched to controls). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0422-9DOI Listing
April 2019
1 Read

Exome and immune cell score analyses reveal great variation within synchronous primary colorectal cancers.

Br J Cancer 2019 Mar 21. Epub 2019 Mar 21.

Applied Tumor Genomics Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland.

Background: Approximately 4% of colorectal cancer (CRC) patients have at least two simultaneous cancers in the colon. Due to the shared environment, these synchronous CRCs (SCRCs) provide a unique setting to study colorectal carcinogenesis. Understanding whether these tumours are genetically similar or distinct is essential when designing therapeutic approaches. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41416-019-0427-4
Publisher Site
http://dx.doi.org/10.1038/s41416-019-0427-4DOI Listing
March 2019
2 Reads

p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy.

Br J Cancer 2019 Apr 21;120(8):797-805. Epub 2019 Mar 21.

Department of Pathology, Seoul National University College of Medicine, Seoul, South Korea.

Background: We attempted to elucidate whether p53 expression or TP53 mutation status was associated with cancer-specific survival in adjuvant FOLFOX-treated patients with stage III or high-risk stage II colorectal cancer (CRC).

Methods: We analysed CRCs (N = 621) for the presence of TP53 alterations and for p53 expression, using targeted resequencing and immunohistochemistry. CRCs were grouped into four subsets according to the p53 expression status, which included p53-no, mild, moderate and strong expression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0429-2DOI Listing
April 2019
4.836 Impact Factor

Correction: Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.

Br J Cancer 2019 Apr;120(8):870

Center for Cancer Immune Therapy, Department of Hematology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.

Since the publication of this paper, the authors noticed that the funding information was not complete. The correct funding information is now shown in the Acknowledgements section. Acknowledgements The studies were supported by grants from the OvaCure Foundation, the Danish Cancer Society Research Foundation, the Anticancer Fund, Aase og Ejnar Danielsens Foundation and the Independent Research Fund Denmark (grant number DFF-4183-00597). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0425-6DOI Listing
April 2019
1 Read

Recommendations for determining HPV status in patients with oropharyngeal cancers under TNM8 guidelines: a two-tier approach.

Br J Cancer 2019 Apr 20;120(8):827-833. Epub 2019 Mar 20.

Centre for Cell Research and Cell Biology, Queen's University Belfast, Belfast, Northern Ireland, UK.

Background: TNM8 staging for oropharyngeal squamous cell carcinomas (OPSCC) surrogates p16 immunohistochemistry for HPV testing. Patients with p16+ OPSCC may lack HPV aetiology. Here, we evaluate the suitability of TNM8 staging for guiding prognosis in such patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0414-9DOI Listing
April 2019
3 Reads

Serious adverse events in African-American cancer patients with sickle cell trait and inherited haemoglobinopathies in a SEER-Medicare claims cohort.

Br J Cancer 2019 Apr 20;120(8):861-863. Epub 2019 Mar 20.

Department of Community Medicine and Health Care, UConn School of Medicine, Farmington, CT, USA.

African-American (AA) cancer patients have long-experienced worse outcomes compared to non-Hispanic whites (NHW). No studies to date have evaluated the prognostic impact of sickle cell trait (SCT) and other inherited haemoglobinopathies, of which several are disproportionately high in the AA population. In a cohort analysis of treated patients diagnosed with breast or prostate cancer in the linked SEER-Medicare database, the relative risk (RR) for ≥1 serious adverse events (AEs), defined as hospitalisations or emergency department visits, was estimated for 371 AA patients with a haemoglobinopathy (AA+) compared to patients without haemoglobinopathies (17,303 AA-; 144,863 NHW-). Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41416-019-0416-7
Publisher Site
http://dx.doi.org/10.1038/s41416-019-0416-7DOI Listing
April 2019
4 Reads

Correction: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group.

Br J Cancer 2019 Apr;120(8):869

Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA.

The authors have noticed that the final paragraph of the Results section contains errors in the number of patients involved. The correct number of patients is included in the text below. These errors do not affect the Figure referenced. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0424-7DOI Listing
April 2019
1 Read

Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance.

Br J Cancer 2019 Apr 18;120(8):791-796. Epub 2019 Mar 18.

Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr., Tampa, FL, 33612, USA.

Background: Bypass activation of Src family kinases can confer resistance to EGFR tyrosine kinase inhibitors (TKIs) based on preclinical models. We prospectively assessed the safety and clinical activity of dasatinib and afatinib in combination for patients with resistant EGFR-mutant lung cancer.

Methods: An open-label, dose-escalation phase 1/2 trial (NCT01999985) with 2-stage expansion was conducted with 25 lung cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0428-3DOI Listing

Correction: Hopefully devoted to Q: targeting glutamine addiction in cancer.

Br J Cancer 2019 Mar 14. Epub 2019 Mar 14.

Oncogenes and Tumour Metabolism Laboratory, The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK.

This article was originally published under a CC BY NC SA License, but has now been made available under a CC BY 4.0 License. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0432-7DOI Listing

Family history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk.

Br J Cancer 2019 Apr 14;120(8):848-854. Epub 2019 Mar 14.

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA.

Background: Individuals with a family history of cancer may be at increased risk of pancreatic cancer. Ashkenazi Jewish (AJ) individuals carry increased risk for pancreatic cancer and other cancer types.

Methods: We examined the association between family history of cancer, AJ heritage, and incident pancreatic cancer in 49 410 male participants of the prospective Health Professionals Follow-up Study. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41416-019-0426-5
Publisher Site
http://dx.doi.org/10.1038/s41416-019-0426-5DOI Listing
April 2019
21 Reads

High filamin-C expression predicts enhanced invasiveness and poor outcome in glioblastoma multiforme.

Br J Cancer 2019 Apr 14;120(8):819-826. Epub 2019 Mar 14.

Department of Neurosurgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.

Background: Glioblastoma multiforme (GBM), the most common brain malignancy in adults, is generally aggressive and incurable, even with multiple treatment modalities and agents. Filamins (FLNs) are a group of actin-binding proteins that regulate the actin cytoskeleton in cells. However, the role of FLNs in malignancies-particularly in GBM-is unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0413-xDOI Listing

Correction: Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.

Br J Cancer 2019 Apr;120(8):868

Institute of Cancer Sciences, University of Glasgow, Glasgow, G61 1QH, UK.

This article was originally published under a CC BY NC SA License, but has now been made available under a CC BY 4.0 License. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0433-6DOI Listing

Revisiting immune escape in colorectal cancer in the era of immunotherapy.

Br J Cancer 2019 Apr 13;120(8):815-818. Epub 2019 Mar 13.

Department of Pathology, Leiden University Medical Center, 2333ZA, Leiden, The Netherlands.

In colorectal cancer (CRC), T-cell checkpoint blockade is only effective in patients diagnosed with mismatch repair-deficient (MMR-d) cancers. However, defects in Human Leukocyte Antigen (HLA) class I expression were reported to occur in most MMR-d CRCs, which would preclude antigen presentation in these tumours, considered essential for the clinical activity of this immunotherapeutic modality. We revisited this paradox by characterising HLA class I expression in two independent cohorts of CRC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0421-xDOI Listing
April 2019
1 Read

The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case-control study.

Br J Cancer 2019 Apr 12;120(8):834-839. Epub 2019 Mar 12.

Medical Oncology Unit, Clinical Cancer Centre, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Background: Deleterious polymorphisms in the gene encoding DPD (DPYD) may result in severe reduction of DPD enzymatic activity that causes life-threatening toxicities when the standard dose of fluorouracil is used. The best panel of single-nucleotide polymorphism (SNPs) of DPYD is not well defined.

Methods: In 2011, we began screening DPYD*2A in patients candidate for fluoropyrimidine-based chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0423-8DOI Listing
April 2019
6 Reads

Correction: Association of symptoms and interval breast cancers in the mammography-screening programme: population-based matched cohort study.

Br J Cancer 2019 Apr;120(7):773-774

Mass Screening Registry, Finnish Cancer Registry, FI-00130, Helsinki, Finland.

The authors report that the labels indicating the symptom types and no symptom lines in the original version of Figure 2 were missing. The correct version of Figure 2 with the labels included is provided below. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0417-6DOI Listing

Correction: Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease.

Br J Cancer 2019 Apr;120(8):867

Oncogenetics, Division of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.

This article was originally published under the standard License to Publish, but has now been made available under a CC BY 4.0 license. The PDF and HTML versions of the paper have been modified accordingly. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0419-4DOI Listing

Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study.

Br J Cancer 2019 Apr 6;120(7):697-702. Epub 2019 Mar 6.

Sorbonne Paris - Cité, Paris Descartes University, Department of Gastroenterology and GI Oncology, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.

Background: Ampullary adenocarcinoma (AA) originates from either intestinal (INT) or pancreaticobiliary (PB) epithelium. Different prognostic factors of recurrence have been identified in previous studies.

Methods: In 91 AA patients of the AGEO retrospective multicentre cohort, we evaluated the centrally reviewed morphological classification, panel markers of Ang et al. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0415-8DOI Listing
April 2019
1 Read

The impact of psychiatric utilisation prior to cancer diagnosis on survival of solid organ malignancies.

Br J Cancer 2019 Apr 6;120(8):840-847. Epub 2019 Mar 6.

Department of Surgery, Division of Urology, University of Toronto, University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada.

Background: Among patients with cancer, prior research suggests that patients with mental illness may have reduced survival. The objective was to assess the impact of psychiatric utilisation (PU) prior to cancer diagnosis on survival outcomes.

Methods: All residents of Ontario diagnosed with one of the top 10 malignancies (1997-2014) were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0390-0DOI Listing

Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study.

Br J Cancer 2019 Apr 5;120(7):689-696. Epub 2019 Mar 5.

Japanese Foundation for Multidisciplinary Treatment of Cancer, Tokyo, Japan.

Background: Up to 6-months oxaliplatin-containing regimen is now widely accepted as a standard adjuvant chemotherapy for stage III colorectal cancer (CRC). However, oral fluoropyrimidine monotherapy is used for some part of patients, especially in Asian countries including Japan, and its optimal duration is yet to be fully investigated.

Methods: A total of 1306 patients with curatively-resected stage III CRC were randomly assigned to receive capecitabine (2500 mg/m/day) for 14 out of 21 days for 6 (n = 654) or 12 (n = 650) months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0410-0DOI Listing
April 2019
3 Reads

Correction: Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy.

Br J Cancer 2019 Apr;120(7):772

Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.

Since the publication of this paper, the authors noticed that the funding information for Maureen A. Su was not included. Therefore the authors would like to add the following information to the Acknowledgements section. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0418-5DOI Listing
April 2019
1 Read

A novel approach to modelling transcriptional heterogeneity identifies the oncogene candidate CBX2 in invasive breast carcinoma.

Br J Cancer 2019 Apr 1;120(7):746-753. Epub 2019 Mar 1.

Department of Systems and Computational Biology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY, 10461, USA.

Background: Oncogenes promote the development of therapeutic targets against subsets of cancers. Only several hundred oncogenes have been identified, primarily via mutation-based approaches, in the human genome. Transcriptional overexpression is a less-explored mechanism through which oncogenes can arise. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41416-019-0387-8
Publisher Site
http://dx.doi.org/10.1038/s41416-019-0387-8DOI Listing
April 2019
3 Reads

SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment.

Br J Cancer 2019 Apr 28;120(7):728-745. Epub 2019 Feb 28.

The Institute of Genetics and Cytology, Northeast Normal University, Changchun, China.

Background: SHON nuclear expression (SHON-Nuc) was previously reported to predict clinical outcomes to tamoxifen therapy in ERα breast cancer (BC). Herein we determined if SHON expression detected by specific monoclonal antibodies could provide a more accurate prediction and serve as a biomarker for anthracycline-based combination chemotherapy (ACT).

Methods: SHON expression was determined by immunohistochemistry in the Nottingham early-stage-BC cohort (n = 1,650) who, if eligible, received adjuvant tamoxifen; the Nottingham ERα early-stage-BC (n = 697) patients who received adjuvant ACT; and the Nottingham locally advanced-BC cohort who received pre-operative ACT with/without taxanes (Neo-ACT, n = 120) and if eligible, 5-year adjuvant tamoxifen treatment. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41416-019-0405-x
Publisher Site
http://dx.doi.org/10.1038/s41416-019-0405-xDOI Listing
April 2019
6 Reads
4.836 Impact Factor

Reproductive factors, exogenous hormone use and incidence of melanoma among women in the United States.

Br J Cancer 2019 Apr 28;120(7):754-760. Epub 2019 Feb 28.

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services, Rockville, MD, USA.

Background: Although the photosensitising effects of oestrogens may increase the impact of ultraviolet radiation (UVR) on melanoma risk, few prospective studies have comprehensively assessed the association between oestrogen-related factors and melanoma.

Methods: We examined the associations between reproductive factors, exogenous oestrogen use and first primary invasive melanoma among 167 503 non-Hispanic white, postmenopausal women in the NIH-AARP Diet and Health Study. Satellite-based ambient UVR estimates were linked to geocoded residential locations of participants at study baseline. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0411-zDOI Listing
April 2019
4 Reads

Correction: Development and validation of a novel risk score for the detection of insignificant prostate cancer in unscreened patient cohorts.

Br J Cancer 2019 Apr;120(7):771

Department of Urology, University College London Hospital, London, UK.

Since the publication of this paper, the authors noticed that Amar Ahmad was not credited as contributing equally to the paper. He should be considered as a joint first author with Lorenzo Dutto. In addition, the author Ashwin Sridhar was incorrectly listed as Ashwin Shridhar, and the author Gregory L. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0408-7DOI Listing
April 2019
2 Reads

High hepatic expression of PDK4 improves survival upon multimodal treatment of colorectal liver metastases.

Br J Cancer 2019 Apr 27;120(7):675-688. Epub 2019 Feb 27.

Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany.

Background: Patients with borderline resectable colorectal liver metastases (CRLM) frequently receive neoadjuvant chemotherapy (NC) to reduce tumour burden, thus making surgical resection feasible. Even though NC can induce severe liver injury, most studies investigating tissue-based prognostic markers focus on tumour tissue. Here, we assessed the prognostic significance of pyruvate-dehydrogenase-kinase isoenzyme 4 (PDK4) within liver tissue of patients undergoing surgical resection due to CRLM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0406-9DOI Listing
April 2019
3 Reads

Tissue-infiltrating immune cells as prognostic markers in oral squamous cell carcinoma: a systematic review and meta-analysis.

Br J Cancer 2019 Apr 27;120(7):714-727. Epub 2019 Feb 27.

Department of Medical Biology, Faculty of Health Sciences, University of Tromsø - The Arctic University of Norway, 9037, Tromsø, Norway.

Background: Various immune cells have been suggested as prognostic markers for cancer patients. In this article, we present a systematic review and meta-analysis of studies assessing the prognostic value of tissue-infiltrating immune cells in oral cancer and discuss the reporting quality of these studies.

Methods: We performed a systematic literature search and included studies using immunohistochemistry and survival analysis to assess the prognostic value of tumour-infiltrating T cells, B cells, macrophages, dendritic cells, mast cells and natural killer cells in oral cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0409-6DOI Listing

Body mass index and Hodgkin's lymphoma: UK population-based cohort study of 5.8 million individuals.

Br J Cancer 2019 Apr 27;120(7):768-770. Epub 2019 Feb 27.

London School of Hygiene and Tropical Medicine, London, UK.

Previous epidemiological studies describe a positive association between body mass index (BMI) and Hodgkin's lymphoma, mainly in obese vs. normal weight individuals. We examined the shape of this relationship in individuals aged 16 years or older, using primary care data from the United Kingdom's Clinical Practice Research Datalink. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0401-1DOI Listing